JY
FDMT icon

Jeff Yass’s 4D Molecular Therapeutics FDMT Stock Holding History

Jeff Yass’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$162K Sell
12,161
-112,067
-90% -$1.09M ﹤0.01% 12145
2026
Q1 		$1.16M Sell
124,228
-1,785
-1% -$15.5K ﹤0.01% 7501
2025
Q4 		$945K Sell
126,013
-6,799
-5% -$69K ﹤0.01% 7319
2025
Q3 		$1.15M Buy
132,812
+8,013
+6% +$47.9K ﹤0.01% 7009
2025
Q2 		$463K Buy
124,799
+54,079
+76% +$190K ﹤0.01% 9350
2025
Q1 		$228K Buy
70,720
+37,991
+116% +$179K ﹤0.01% 10668
2024
Q4 		$182K Buy
32,729
+7,956
+32% +$62.4K ﹤0.01% 10826
2024
Q3 		$268K Sell
24,773
-9,250
-27% -$154K ﹤0.01% 9835
2024
Q2 		$714K Buy
34,023
+17,431
+105% +$437K ﹤0.01% 7364
2024
Q1 		$529K Sell
16,592
-23,890
-59% -$609K ﹤0.01% 8372
2023
Q4 		$820K Buy
40,482
+20,142
+99% +$265K ﹤0.01% 7470
2023
Q3 		$259K Sell
20,340
-2,208
-10% -$36.9K ﹤0.01% 9673
2023
Q2 		$407K Sell
22,548
-56,026
-71% -$1.03M ﹤0.01% 8789
2023
Q1 		$1.35M Buy
78,574
+46,348
+144% +$901K ﹤0.01% 6064
2022
Q4 		$716K Buy
32,226
+21,668
+205% +$335K ﹤0.01% 6967
2022
Q3 		$85K Buy
10,558
+155
+1% +$1.4K ﹤0.01% 11824
2022
Q2 		$73K Sell
10,403
-9,953
-49% -$96.8K ﹤0.01% 11739
2022
Q1 		$308K Sell
20,356
-13,500
-40% -$212K ﹤0.01% 10212
2021
Q4 		$743K Buy
+33,856
New +$830K ﹤0.01% 8087

Other funds holding FDMT

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Jeff Yass's FDMT Position: Q2 2026 in Review

Jeff Yass reduced its 4D Molecular Therapeutics (FDMT) stake by 90% in Q2 2026, selling an estimated $1.09M and leaving 12,161 shares worth $162K. The position accounts for ﹤0.01% of the portfolio, ranked #12145.

Jeff Yass first reported a position in FDMT in Q4 2021 and has held it in 19 quarters since. The position peaked at $1.35M in Q1 2023. 157 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

  • Jeff Yass held 12,161 shares of 4D Molecular Therapeutics worth $162K as of Q2 2026.
  • Jeff Yass sold 112,067 4D Molecular Therapeutics shares in Q2 2026, an estimated $1.09M.
  • 4D Molecular Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #12145 holding.
  • Jeff Yass first reported a position in 4D Molecular Therapeutics in Q4 2021 and has held it in 19 quarters since.
  • Jeff Yass's 4D Molecular Therapeutics position peaked at $1.35M in Q1 2023.
  • 157 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.